Press releases

Boston Scientific announced the commencement of a cash tender offer for up to $1.0 billion of outstanding senior notes.

Boston Scientific will webcast its conference call with financial results and business highlights for Q3 ended September 30, 2019.

Study of abbreviated antiplatelet therapy for patients at high risk for bleeding after percutaneous coronary intervention.

Notably, key data from the EVOLVE Short DAPT study of the SYNERGY stent will be featured during a late-breaking science session.

Boston Scientific CEO Mike Mahoney will participate in a conference in September 2019. Learn how to join the webcast or watch the replay.

System is designed to treat Parkinson's Disease symptoms by delivering precisely targeted electrical stimulation.

BTG acquisition brings best-in-class minimally-invasive technologies for procedures targeting cancer and vascular diseases to Boston Scientific.

Physicians will have continued access to the Eluvia™ Drug-Eluting Vascular Stent (DES) System to treat their patients with peripheral artery disease (PAD).

Boston Scientific will participate in an upcoming investor conference in August 2019. A live webcast and replay will be available.

"The consistent execution of our global teams continues to help us grow the majority of our businesses faster than the market,” said Mike Mahoney.